Feb 23, 2014 7:37 PM PST
Biotechnology has been the hottest sector of the market for the better part of two years. It’s true, 300% annual gains have almost become the norm for investors in this space. Though the question remains: what makes for a 300% gain? What are the events that...
Jan 7, 2014 8:50 AM PST
ARTH could revolutionize the hemostasis market with AC5. This market is currently $4b per year and expected to almost double i
Jan 2, 2014 6:24 AM PST
An overview of top performing biotech stocks.
Dec 23, 2013 6:03 AM PST
One small biotech company focused on this terrible affliction, OncoSec Medical, Inc (ONCS), reported great trial data this week that offers renewed hope for current and future patients of skin cancer.
Nov 18, 2013 8:05 AM PST
Companies developing treatments for Melanoma can be very profitable for investors
Nov 5, 2013 8:32 AM PST
As a long-term investor looking to invest across many sectors, biotechnology is one that is worth my extra research. The area I find myself most focused on within the biotechnology sector is, of course, cancer research. It may be because of the tremendous press...
Sep 25, 2013 6:40 AM PDT
Last year I wrote an article entitled, "Alternative Cancer Therapies Currently Overlooked By Investors", covering OncoSec Medical (ONCS.OB), Inovio Pharmaceuticals (INO), Dendreon Corp (DNDN) and Celgene (CELG). My main focus in that specific article were companies...
Aug 26, 2013 6:47 AM PDT
If the action from Inovio Pharmaceuticals Inc. (NYSEMKT:INO) is any clue, then Prana Biotechnology Limited (NASDAQ:PRAN) may be ready to make a sizable pullback.
Aug 6, 2013 11:47 AM PDT
OncoSec Medical (OTC: ONCS) and Inovio Pharmaceuticals (NYSE: INO) have been exceptional performers in recent trading due to investor excitement over electroporation technology and recent data that was presented that supports this process of drug delivery enhancement. In the last month alone, OncoSec moved up 44%. Inovio has moved up 213% on substantial volume. Since my last note, Oncosec has move about 15% higher while Inovio has doubled.
Jul 16, 2013 6:58 AM PDT
Recently presented data from a preclinical study performed using Inovio Pharmaceuticals’ (NYSE: INO) DNA vaccine against the H7N9 strain of avian influenza (bird flu) garnered some interest and buying momentum in INO, although investors seemed even more impressed after the release of the peer-reviewed publication analyzing the data from 2 Phase I trials for Inovio’s PENNVAX-B vaccine, which was delivered using Inovio’s CELLECTRA electroporation device. PENNVAX induced a strong T-cell response in 89% of the patients that had received three doses of the vaccine plus a signaling protein called Interleukin-12, inducing a best-in-class immune system response against HIV.